5 Best Peptides for Arousal

What to Know Before Choosing a Peptide for Arousal

The peptide landscape for sexual arousal is narrower than it is for goals like tissue repair or metabolic health, but it is far from empty. A handful of compounds have built real followings, and they work through mechanisms that are genuinely distinct from conventional sexual health treatments. Traditional options like PDE5 inhibitors act on blood flow in the periphery. Several of the peptides on this list work upstream of that, acting on the central nervous system to influence desire, motivation, and the neurological experience of arousal itself.

Every compound in this guide earned its place by a single standard: people use it for arousal, or are actively discussing using it. FDA approval status, prescription requirements, and the depth of the clinical evidence are all factors that get described honestly inside each entry. They are not used as filters to decide whether a compound belongs here at all. That means this guide includes an FDA-approved prescription compound, compounds available through telemedicine or compounding pharmacies, and research-only compounds whose human data is limited. The evidence for each is stated plainly so the reader can weigh the options with a clear picture of what is known and what is not.

The numbering here is a spine for the list, not a verdict. The order reflects how prominently each compound appears in published research and documented real-world use, not a recommendation that any one compound is better for you than another. The right choice depends on your situation, your health history, and what you work through with the MyPeptidePal app.

1. PT-141: The Only FDA-Approved Central Arousal Peptide

PT-141, known generically as bremelanotide and sold under the brand name Vyleesi, is the only peptide the FDA has approved specifically for sexual arousal. That approval came in June 2019 and covers premenopausal women with hypoactive sexual desire disorder, a condition defined by persistent low sexual desire that causes personal distress. For men, PT-141 is used off-label only, since no FDA-approved peptide treatment for male sexual desire currently exists, but physician-supervised off-label use is established and supported by Phase 2 clinical data.

What makes PT-141 different from every other treatment in this category is where it acts. PDE5 inhibitors like sildenafil work by relaxing smooth muscle and increasing blood flow to the genitals, a peripheral mechanism that facilitates erection but does nothing to generate the neurological experience of wanting sex. PT-141 bypasses that entirely. It is a synthetic melanocortin peptide that binds to MC3R and MC4R receptors, two melanocortin receptor subtypes concentrated in the hypothalamic regions of the brain that govern sexual motivation. Think of MC3R and MC4R as on-switches for the brain's desire circuitry: when PT-141 flips them, it sets off a cascade involving dopamine release in the nucleus accumbens, the brain's primary reward and motivation center, along with increases in norepinephrine in arousal circuits and modulation of oxytocin pathways. The result is central enhancement of desire generated from the brain down, rather than from blood flow up.

The clinical evidence for PT-141 in women is the strongest in this category. The pivotal Phase 3 RECONNECT trials enrolled over 1,200 premenopausal women with HSDD across two parallel randomized, double-blind, placebo-controlled studies. Both met their primary endpoints. Sixty-seven percent of participants taking bremelanotide reported feelings of sexual desire compared to twenty-two percent on placebo, and seventy-two percent reported genital arousal compared to thirty-nine percent on placebo. Effect sizes on the desire and distress reduction scales ranged from 0.49 to 0.62, which represents a clinically meaningful difference. An fMRI study also showed that bremelanotide activation of MC4R altered brain responses to erotic stimuli and enhanced desire for at least twenty-four hours after a single dose.

For men, a Phase 2 study of 342 participants with erectile dysfunction who had not responded to sildenafil found that intranasal PT-141 produced a positive clinical response in 33.5 percent of subjects compared to 8.5 percent on placebo. No large Phase 3 trial in men has been completed, and the FDA has not approved PT-141 for male use, but that Phase 2 data provides meaningful clinical support for physician-supervised off-label use.

The side effect profile is real and worth understanding before choosing this compound. Nausea is the most common adverse effect, reported in roughly 40 percent of clinical trial participants and at higher rates in community use. Flushing of the face, neck, and chest follows closely. PT-141 also produces a transient blood pressure increase, which makes it contraindicated for people with uncontrolled hypertension or cardiovascular disease. Hyperpigmentation of skin, gums, or breast tissue can occur with overuse. For women with an HSDD diagnosis, access is available via prescription through qualified physicians and telemedicine platforms. For men, it requires a physician willing to prescribe off-label.

2. Kisspeptin-10: The Emerging First-in-Class Option for Male HSDD

Kisspeptin-10 occupies a distinctive position in this field because it addresses a gap PT-141 does not fill: there is currently no FDA-approved treatment for men with low sexual desire. Kisspeptin-10 is now the most clinically credentialed investigational option for that specific problem, based on randomized trial data published in JAMA Network Open from a research group at Imperial College London.

Kisspeptin is an endogenous neuropeptide, meaning the body produces it naturally. It is encoded by the KISS1 gene and functions as an upstream regulator of the hypothalamic-pituitary-gonadal axis, the hormonal cascade that governs sex hormone production. When kisspeptin binds to its receptor, it stimulates the release of gonadotropin-releasing hormone from the hypothalamus, which then drives luteinizing hormone and follicle-stimulating hormone release, ultimately increasing testosterone and estrogen. Kisspeptin also acts more directly on sexual brain processing through kisspeptin receptors in hypothalamic regions tied to sexual motivation. That is a distinct mechanism from both the melanocortin pathway PT-141 uses and the vascular pathway PDE5 inhibitors use.

The Imperial College London trials enrolled 32 men and 32 premenopausal women with HSDD in parallel randomized studies. In men, kisspeptin-10 increased penile tumescence by up to 56 percent compared to placebo, a result that reached statistical significance, and produced improved behavioral measures of sexual desire and arousal. Imaging data showed meaningful changes in the neural circuits that process sexual motivation. In women, kisspeptin reduced activity in brain regions associated with negative self-monitoring during sexual stimuli and increased activity in areas linked to emotional and motivational processing. These are proof-of-concept trials, not pivotal registration studies, and kisspeptin-10 is not approved for any sexual health indication as of 2026. But the quality of that evidence, published randomized clinical trial data in humans with a well-characterized mechanism, puts it ahead of most investigational compounds in this space.

At trial doses, kisspeptin-10 was well tolerated, and the studies did not show the nausea, flushing, or cardiovascular effects that complicate PT-141 use, though long-term safety data is not yet available. Access in 2026 is through research or investigational channels; kisspeptin-10 is not available via standard telemedicine as a sexual health treatment.

3. Melanotan II: Strong Arousal Effects, Significant Skin Consequences

Melanotan II is closely related to PT-141, and understanding the relationship between them clarifies both why it is used for arousal and why it carries risks PT-141 does not. PT-141 was developed as a metabolite of Melanotan II during early research on the melanocortin system. The two peptides share the same core arousal mechanism, agonism at MC3R and MC4R receptors in the hypothalamus, producing central enhancement of sexual desire and motivation through dopamine and related pathways. The critical difference is that Melanotan II also activates MC1R, the melanocortin receptor subtype that drives skin pigmentation by stimulating melanocytes. PT-141 was specifically refined to minimize MC1R activity. Melanotan II was not.

Melanotan II is not approved by the FDA or any major regulatory agency for any indication. It has no established prescription pathway and is accessed as a research peptide. In terms of formal clinical evidence, it is considerably less studied than PT-141 for arousal specifically. Early research in animal models demonstrated proerectile effects via MC4R activation, and the mechanistic plausibility is strong given how closely the arousal pathway mirrors PT-141. Spontaneous erections in men, increased libido, and enhanced orgasmic intensity are all reported across community protocols. There are no Phase 3 randomized controlled trials for arousal in humans, and the evidence for this specific use rests on mechanistic plausibility, early animal research, and user-reported experience.

The cumulative skin darkening is the defining safety concern that separates Melanotan II from PT-141 as a repeat-use arousal compound. Pigmentation builds progressively with each use, is not easily reversible, and affects existing moles and skin features as well as general skin tone. There is theoretical concern about melanoma risk with chronic MC1R stimulation, and any changes in moles during use warrant monitoring. The nausea and flushing profile is similar to PT-141, and spontaneous erections can occur without sexual stimulation, which some users find unwanted. Because it falls outside regulatory oversight, quality control varies entirely by source.

For someone who wants PT-141's arousal mechanism and is willing to accept progressive skin darkening, Melanotan II produces those effects. For most people researching options in 2026, the availability of PT-141 via prescription makes the cumulative pigmentation risk of Melanotan II a significant drawback relative to the approved alternative.

4. Oxytocin: For Emotional Connection and Orgasm Intensity

Oxytocin is an endogenous neuropeptide produced in the hypothalamus and released by the pituitary gland. It plays a well-established role in social bonding, trust, emotional processing, and the physiology of labor and lactation. Within the sexual health context, it occupies a specific niche: not raw libido enhancement, but the emotional and relational texture of sexual experience, including arousal that has an anxiety or connection component, orgasm intensity, and the sense of intimacy during sex.

The mechanism is distinct from the melanocortin peptides. Oxytocin binds to its own receptors in the brain and peripheral tissues, modulating the limbic structures involved in emotional processing. It reduces activity in the amygdala, the brain region that processes threat and anxiety, which is the pathway behind its calming effects during sexual encounters. It also increases dopamine activity in reward circuits and modulates serotonin pathways involved in sexual motivation. For people whose arousal difficulties have a psychological or relational dimension, this mechanism is relevant in a way that a purely desire-signaling compound like PT-141 is not.

Human trial data exists for oxytocin's effects on orgasm in women, with studies showing increased orgasm intensity and duration. The evidence for oxytocin as a standalone treatment for low sexual desire or HSDD is more mixed; clinical results for desire specifically have been inconsistent across studies. The FDA has not approved oxytocin for sexual arousal or HSDD. In the sexual health context, it is available off-label through compounding pharmacies, typically as an intranasal spray, and is used under physician supervision. The community framing around oxytocin consistently distinguishes its role from PT-141: users describe it as adding warmth, connection, and orgasm enhancement to a sexual experience rather than generating desire from scratch. Side effects at typical off-label doses are generally minimal compared to the melanocortin peptides, with no significant cardiovascular or pigmentation concerns.

5. BPC-157: An Emerging Option for Post-SSRI Sexual Dysfunction

BPC-157, short for Body Protection Compound 157, is not primarily an arousal peptide. Its established research base covers tissue repair, gut healing, and injury recovery. It belongs on this list for a specific reason: people with post-SSRI sexual dysfunction are using and discussing it for this purpose in meaningful numbers, and some reports are notable enough to warrant an honest entry.

SSRI antidepressants are well known to blunt sexual desire and diminish orgasmic sensation, and for a subset of patients those effects persist long after stopping the medication, sometimes indefinitely. Conventional treatments for post-SSRI sexual dysfunction are limited. BPC-157 has appeared in community discussions as a compound some users have tried for this condition, with at least one detailed case report describing a return of orgasmic sensation and improvement in morning erections, with effects reportedly maintained over a two-year period.

No published human clinical trials have examined BPC-157 for sexual dysfunction or post-SSRI sexual dysfunction as of 2026. The mechanism by which it might affect sexual function is not well characterized, though proposed pathways include effects on nitric oxide signaling and growth factor pathways that could support neurological recovery in affected circuits. The evidence here is experiential rather than clinical, and a single detailed case report alongside community discussion is a different kind of signal than what supports PT-141 or kisspeptin-10.

BPC-157 is a research peptide with no FDA approval for any indication. For most people whose primary goal is arousal enhancement, it is not the compound to start with. Its place in this list reflects a specific population, people with SSRI-related sexual dysfunction who have not found relief through other means, for whom the community signal is strong enough to be worth knowing about, with the evidence picture stated exactly as it is.

How These Peptides Compare

Frequently Asked Questions

Is PT-141 legal to use and how do people access it?

PT-141 is a prescription medication in the United States, FDA-approved under the brand name Vyleesi for premenopausal women with hypoactive sexual desire disorder. Women with that diagnosis can access it through a physician or a qualifying telemedicine platform. For men, it is used off-label only, meaning a physician can prescribe it but the FDA has not approved it for male sexual dysfunction. Selling PT-141 as a research chemical for human use violates FDA regulations because it is a scheduled prescription drug, not a legal over-the-counter compound.

Are any of these peptides available without a prescription?

Among the five compounds on this list, PT-141 is the one that requires a prescription because it is an FDA-approved drug. Oxytocin is available through compounding pharmacies with a prescription in most jurisdictions. Kisspeptin-10 and BPC-157 exist in research chemical channels without an approved prescription pathway, though neither is approved for human use. Melanotan II is a research peptide with no approved human use pathway and no prescription route anywhere.

How do these peptides compare to Viagra or other PDE5 inhibitors?

PDE5 inhibitors like sildenafil work peripherally by relaxing smooth muscle and increasing blood flow to the genitals, which facilitates erection when sexual stimulation is already present. Most of the peptides on this list, particularly PT-141 and kisspeptin-10, work centrally, acting on brain circuits that govern sexual desire and motivation. That makes them relevant in situations where desire itself is absent rather than where blood flow is the limiting factor. The two approaches address different parts of the problem, and some physicians use them together, though PT-141 combined with PDE5 inhibitors requires caution because of additive hemodynamic effects.

What are the most commonly reported side effects?

For PT-141, nausea and flushing are the most widely reported side effects, with nausea appearing in roughly 40 percent of clinical trial participants and at higher rates in community use. A transient blood pressure increase also occurs and is a meaningful concern for people with cardiovascular conditions. Melanotan II shares the nausea and flushing profile and adds cumulative, progressive skin darkening as its defining concern with repeated use. Kisspeptin-10 was well tolerated in early trials without the nausea or cardiovascular effects seen with PT-141. Oxytocin at typical off-label doses carries a minimal side effect profile.

How long do effects typically last after using PT-141?

In clinical use, PT-141 administered by subcutaneous injection is typically used around 45 minutes before sexual activity, with effects reported to begin within 30 to 90 minutes. Community users commonly report that physical arousal effects last 8 to 10 hours, and fMRI research showing enhanced desire responses to erotic stimuli found the effect persisted for at least 24 hours after a single dose. Individual experiences vary considerably, and side effects like nausea can affect whether the experience is practically useful within that window.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for arousal in one place.